New prodrugs of metformin do not influence the overall haemostasis potential and integrity of the erythrocyte membrane
Open Access
- 1 September 2017
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 811, 208-221
Abstract
No abstract availableKeywords
Funding Information
- National Science Centre in Poland (2016/21/D/NZ7/01548)
- Medical University of Lodz (502-03/3-015-01/502-34-061, 503/3-015-01/503-31-004)
This publication has 36 references indexed in Scilit:
- Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney diseaseClinical Kidney Journal, 2012
- Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic ratsEuropean Journal of Pharmacology, 2011
- Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 2011
- The Overall Hemostasis Potential: A Laboratory Tool for the Investigation of Global HemostasisSeminars in Thrombosis and Hemostasis, 2010
- Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetesDiabetes Research and Clinical Practice, 2005
- Reducing insulin resistance with metformin: the evidence todayDiabetes & Metabolism, 2003
- Beneficial effects of metformin on haemostasis and vascular function in manDiabetes & Metabolism, 2003
- Management of diabetes mellitus and insulin resistance in patients with cardiovascular diseaseThe American Journal of Cardiology, 2003
- In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysisBiomaterials, 2003
- The CLUE Test: A Multiparameter Coagulation and Fibrinolysis Screening Test Using the Platelet AggregometerAmerican Journal of Clinical Pathology, 1975